Bayer announces positive topline results for NUBEQA (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC) Read more
Merck Begins Commercial Production of First GMP-Compliant Manufacturing Line for Cell Culture Media in China Read more
Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics Read more
Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) Read more
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRPa cancer immunology treatment BI 770371 Read more
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer Read more